Electromed, INC

Electromed, Inc. announced record-breaking financial results for Fiscal Year 2026, with significant increases in net revenue and operating income, alongside the planned retirement of its CEO.

Electromed, Inc. announced record financial results for its third quarter of fiscal year 2026, with an 18.4% increase in net revenues and a 76.0% surge in operating income.

Electromed, Inc. reported record net revenues and net income for its fiscal second quarter ended December 31, 2025, marking its thirteenth consecutive quarter of year-over-year growth.

Electromed, Inc. has entered into a new $10 million revolving credit facility with BMO Bank N.A., replacing its previous credit arrangement.

Electromed, Inc. shareholders approved the election of eight directors, ratified RSM US LLP as auditor, and endorsed executive compensation at their annual meeting on November 14, 2025.

Electromed, Inc. announced robust first quarter fiscal 2026 results, marking its twelfth consecutive quarter of year-over-year revenue and net income growth, driven by strong operational execution and market expansion.

Electromed, Inc. announced significant revenue and net income increases for the second quarter and first six months of fiscal year 2026, driven by robust homecare sales.

Electromed, Inc. reported a 15.1% increase in net revenues and a 44.9% rise in net income for the first fiscal quarter ended September 30, 2025, driven by robust homecare and hospital sales.

Electromed's Q3 2025 results show significant revenue growth, particularly in the homecare market, leading to increased profitability.

Electromed, Inc. announces a significant increase in net revenues for the quarter ended December 31, 2024, primarily driven by growth in the homecare market.

Electromed Inc. saw a significant increase in net income and revenue for the quarter ended September 30, 2024, driven by strong performance in the homecare market.

Electromed, Inc. saw a 14.9% increase in net revenue for the third quarter of 2024 compared to the same period last year, despite a temporary disruption from a cybersecurity incident.

Electromed, Inc. announced robust financial results for fiscal year 2025, driven by significant revenue and profit increases across its core airway clearance therapy products.

Electromed Inc. announces a robust fiscal year 2024 with significant revenue growth and increased profitability, primarily driven by its homecare segment.

Electromed's Chief Financial Officer, Bradley M. Nagel, reported a disposition of 674 shares of common stock on June 30, 2026, due to tax withholding obligations.

CEO and President James L. Cunniff exercised 9,700 stock options and subsequently sold a portion of the resulting shares.

Electromed, Inc. CFO Bradley M. Nagel exercised stock options and sold a total of 11,801 shares of common stock.

Electromed, Inc. Director Kathleen Skarvan reported transactions involving the sale of common stock and the acquisition of employee stock options.

Electromed, Inc. Director Kathleen A. Tune was granted 3,000 shares of common stock as restricted stock, scheduled to vest on June 1, 2026.

Electromed, Inc. Director Stan K. Erickson was granted 3,000 shares of restricted common stock, scheduled to vest on June 1, 2026.

Electromed, Inc. announces its 2025 Annual Meeting of Shareholders to vote on director elections, auditor ratification, and executive compensation matters.

Electromed, Inc. announced its 2025 Annual Meeting of Shareholders to be held virtually on November 14, 2025, to vote on director elections, auditor ratification, and executive compensation, following a fiscal year of exceeded financial targets.

ElectroMed, Inc. is set to hold its annual shareholder meeting virtually on November 15, 2024, to vote on key proposals including the election of directors, ratification of the accounting firm, and executive compensation.

Electromed, Inc. will hold its 2024 Annual Meeting of Shareholders virtually on November 15, 2024, to vote on the election of directors, ratification of the appointment of RSM US LLP as the independent registered public accounting firm, and advisory approval of executive compensation.

Summers Value Fund LP and SVP DEAL FUND 1 LP, along with affiliated entities, have reduced their beneficial ownership in Electromed, Inc. to below 5% through a series of common stock sales in February 2025.

The Vanguard Group has filed an amendment to its Schedule 13G for Electromed Inc., reporting zero beneficial ownership due to an internal organizational realignment.

The Vanguard Group has reported a 5.19% beneficial ownership stake in Electromed Inc, holding 435,637 shares of common stock as of June 30, 2025.